Navigation Links
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
Date:1/12/2009

SHELTON, Conn., Jan. 12 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist, CR845. The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the United States and will evaluate the analgesic efficacy and safety of intravenous CR845 during the post-operative period in women following laparoscopic-assisted hysterectomy. The trial is expected to enroll 120 patients, who will be randomly selected for treatment with one of two doses of CR845 or placebo. Results from the study are expected in the second half of 2009.

The Company also expects to initiate a Phase I study of an oral formulation of CR845 later in 2009.

About CR845

A previous Phase Ia single-center clinical trial of intravenous CR845 evaluated the safety, tolerability, pharmacokinetic profile, and pharmacological activity of the compound in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown to be safe at all doses investigated, with no reports of serious side effects or adverse central nervous system activity. Linear, dose-proportional increases in systemic exposure to CR845 were observed. Low doses of CR845 stimulated physiological biomarkers of peripheral kappa opioid receptor activity, and also produced plasma levels of drug associated with analgesic efficacy in multiple preclinical studies.

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibited analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Oral bioavailability was confirmed in multiple species. In con
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
4. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
5. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
6. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
9. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
10. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
11. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... COSTA MESA, Calif. , July 25, 2014 /PRNewswire-iReach/ ... Peter Nieto as the new Vice President ... industry for over 30 years in a number of ... CROs in the industry. These positions were primarily related ... has obtained over the past 30 years makes him ...
(Date:7/25/2014)... OF SPAIN, Trinidad and Tobago , July ... Division of the Trinidad & Tobago Ministry of ... market, an innovative therapy that significantly increases the cure ... for patients infected with the genotype 1 virus. ... under the trade brand INCIVO®. ...
(Date:7/25/2014)... Group Inc (OTC: SLNX) is pleased to announce that ... the Letter of Intent issued on July 11, 2014 ... Charles R. Shirley , Managing Director ... David Pecoraro and Buzznbrewz.com join SLNX,s team.  ... and developed a tremendous network of contacts who have ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... , , TOKYO ... Daiichi Sankyo Company, Limited (TSE: 4568), announced today that ... for edoxaban, its investigational oral Factor Xa inhibitor. This new ... and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) ...
... , , SOMERSET, N.J. , Feb. ... trials in patients with acute low back pain (ALBP) who ... functionality and reduced disability after three days of treatment, as ... being presented this week at the 26th annual meeting of ...
Cached Medicine Technology:Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 2Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 3Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 4Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 5SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 2SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 3SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 4SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 5
(Date:7/27/2014)... have shown that a powerful drug given at the ... the early risk of rejection, but that it also ... be used after the operation. , The key results ... at the World Transplant Congress in San Francisco today. ... conundrum: the powerful combinations of treatments used to prevent ...
(Date:7/27/2014)... 27, 2014 The report, “Glass ... Market By Raw Material, By Manufacturing Process, By ... & By Geography – Global Trends & Forecast ... Composites market with an analysis and forecast by ... tables and 107 figures spread through 347 slides ...
(Date:7/27/2014)... The inaugural Latino Conservation Action Week ... protecting our environment and getting outdoors. During the week, ... on hiking or camping outings, participate in community events ... permanently protecting our land, water and air. , ... on the environment like the need to protect our ...
(Date:7/27/2014)... constant expansion of companies across the globe has led ... factors that have increased this demand include the application ... learning and development, security and safety, and knowledge sharing ... video market value has crossed $11.21 billion in 2013 ... with a compound annual growth rate (CAGR) of 25.97%. ...
(Date:7/27/2014)... York, NY (PRWEB) July 27, 2014 ... Tea Production industry has fared well, thanks to ... and coffee blends. According to the Coffee Association of ... available), Canadians consume 2.7 cups of coffee per day. ... light on the health benefits of drinking tea on ...
Breaking Medicine News(10 mins):Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Coffee and Tea Production in Canada Industry Market Research Report Now Available from IBISWorld 3
... a Healthier Future, WASHINGTON, Oct. 22 ... is launching a,national health campaign to vaccinate more ... than 1.5 million insecticide-treated,mosquito nets to prevent the ... than 1 million African children each year. ...
... The University of Alabama at Birmingham (UAB) Center ... a $3.8 million grant renewal from the U.S. Department ... arthritic and musculoskeletal diseases and their treatments. , The ... in the nation, to continue its often-cited research on ...
... new model of nonprofit fund-raising events and raises ... more than ... and women from,across the country climbed more than 1,000 stairs ... Up to Fight Diabetes,fund-raising challenge. The Step Up event raised ...
... snooze-time, experts say , , SATURDAY, Oct. 20 (HealthDay News) -- ... Sunday in November, you should use that extra hour to ... , Too often, work and family responsibilities take precedence over ... Sleep Disorders Clinic at Stanford University Medical Center in Palo ...
... Inc. (Nasdaq: AMCS ),a leader in radiology and medical image ... results,for the second quarter ended September 30, 2007, before the market ... ), WHEN: ... -- Call begins promptly at 8:30 a.m. (Eastern Time), ...
... 19 Broadband Wireless,International Corporation (Pink Sheets: BBAN) ... discussions with Mr. Kenneth Andam in,connection with HealthPitch, ... to a continuing business relationship,connecting Mr. Andam and ... of good faith negotiations have commenced between BBAN ...
Cached Medicine News:Health News:Government of Madagascar and Coalition of Global Partners Launch Measles and Malaria Prevention Campaign 2Health News:Government of Madagascar and Coalition of Global Partners Launch Measles and Malaria Prevention Campaign 3Health News:Musculoskeletal center wins $3.8 million research grant 2Health News:American Diabetes Association Steps Up to Fight Diabetes 2Health News:American Diabetes Association Steps Up to Fight Diabetes 3Health News:Fall Time Change Could Be Boon for Sleep 2Health News:AMICAS Schedules Third Quarter Earnings Call 2Health News:Broadband Wireless International Corporation Announces the Commencement of Good Faith Talks with HealthPitch 2
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Liquichek Serum Volatiles Control is a bilevel liquid control with assayed values for the most widely measured volatile compounds....
... Urine Control contains a comprehensive ... that monitor tests for general ... hormones. It also contains hCG ... microalbumin at levels suitable for ...
Medicine Products: